Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Immunomedics Inc (IMMU)

Immunomedics Inc (IMMU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Portnoy Law Firm: Tactile Systems Technology, Inc., Pintec Technologies Holdings Limited, and Immunomedics, Inc. Investors Have Limited Amount of Time Before Class Action Deadline

Investors with losses are encouraged to contact Attorney Lesley F. Portnoy.

TCMD : 7.02 (-3.84%)
PT : 1.3800 (-5.48%)
IMMU : 87.86 (+0.05%)
BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Board Appointment of Dr. Khalid Islam

Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with a high unmet medical need, today announced...

PCSA : 3.02 (+7.47%)
FENC : 5.71 (+2.33%)
IMMU : 87.86 (+0.05%)
Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors

HANOVER, MD, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...

PCSA : 3.02 (+7.47%)
FENC : 5.71 (+2.33%)
IMMU : 87.86 (+0.05%)
Gilead Sciences Completes Acquisition of Immunomedics, Inc.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: IMMU) for approximately $21 billion in the aggregate.

GILD : 62.36 (+0.89%)
IMMU : 87.86 (+0.05%)
Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma

MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...

IMMU : 87.86 (+0.05%)
Moore Kuehn Encourages IMMU, MOBL, MR, and SCBH Investors to Contact Law Firm

NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether...

IMMU : 87.86 (+0.05%)
MOBL : 7.04 (unch)
SCBH : 17.2500 (+1.47%)
MR : 5.36 (-1.29%)
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Investors About Its Ongoing Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, RST, IMMU, VAR

NEW YORK, NY / ACCESSWIRE / September 26, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) concerning potential violations of...

GILD : 62.36 (+0.89%)
CBMG : 19.75 (unch)
RST : 29.99 (unch)
IMMU : 87.86 (+0.05%)
VAR : 177.07 (-0.02%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of IMMU, VRTU, RST, and CBMG Buyouts

WILMINGTON, Del., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating:

IMMU : 87.86 (+0.05%)
VRTU : 51.33 (+0.03%)
RST : 29.99 (unch)
CBMG : 19.75 (unch)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Reminds Investors About Its Ongoing Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, AKCA, VRTU, IMMU

NEW YORK, NY / ACCESSWIRE / September 21, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) concerning potential violations of...

GILD : 62.36 (+0.89%)
CBMG : 19.75 (unch)
AKCA : 18.17 (+0.17%)
VRTU : 51.33 (+0.03%)
IMMU : 87.86 (+0.05%)
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer

Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC)

IMMU : 87.86 (+0.05%)

Barchart Exclusives

2 BDC Stocks Yield Over 10% With Excellent Covered Call Plays
These 2 business development companies (BDCs) yield over 10%, even before some extra quarterly dividends they have been issuing. In addition, they off excellent covered call opportunities for investors. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar